Successful therapy confirmed for newborns with the fatal metabolic disorder MoCD type A

Early administration of the drug Fosdenopterin/rcPMP improves the chances of survival of infants with MoCD type A and promotes the development of brain functions.

Early administration of the drug Fosdenopterin/rcPMP improves the chances of survival of infants with MoCD type A and promotes the development of brain functions.

Read more https://www.sciencedaily.com/releases/2025/04/250403143943.htm